DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Biosimilars Insights

Size the opportunity in this lucrative market and evaluate the disruptive effects biosimilars are having on the pharma industry

  • Assess the current and future market size for biosimilars across six therapy areas
  • Evaluate the global biosimilar pipeline and launch timing in major markets
  • Track how payers and physicians respond to launches of biosimilars and understand the factors that will drive or limit use
  • Review case study examples of successful corporate strategies deployed in the biosimilars space

 

Schedule a demo

“Despite the attractiveness of the biosimilars space, manufacturers must account for the not-insignificant development and commercialization hurdles in the process to market entry. Substantial capital investment and expertise in biological development is mandatory.”

Marta Delgado

Business Insights Analyst

Methodology

  • Coverage of the biosimilars market since 2006
  • Market sizing for over 30 reference brand biologics
  • 10-year interactive forecast covering US, Europe, and Japan
  • Annual surveys of over 500 physicians across six specialties and in-depth interviews with payers from the US and EU